Rima Patel
@rimapatelmd
Breast Medical Oncologist @MountSinaiNYC @TischCancer
ID: 4903109591
13-02-2016 00:25:17
26 Tweet
280 Followers
307 Following
Grateful to be attending my first in-person ASCO meeting with a phenomenal group of Mount Sinai Hematology/Oncology Fellowship co-fellows! #ASCO22 The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai
Excited to reconnect ASCO with this awesome crew of soon to be breast oncologists! 💃🏽 #womeninonc Laura Huppert, MD Alaina J. Kessler, MD, MPH Rima Patel
Great to be at #ASCO22 and share our findings on the correlation between Ki67 and Oncotype #bcsm The Tisch Cancer Institute Mount Sinai Hematology/Oncology Fellowship
.Rima Patel presented today at #ASCO22: Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score in early #breastcancer. meetings.asco.org/abstracts-pres… Mount Sinai Health System Icahn School of Medicine at Mount Sinai
Beaming as I watch Laura Huppert, MD present at #ASCO22 as a fellow! This is a big deal 🙌🏼
Enjoying our last day in #Vail for the AACR ASCO #MCCR workshop with these amazing women oncologists! Sridevi Rajeeve, MD Krithika Shanmugasundaram @PrincessMark17
Representing Icahn School of Medicine at Mount Sinai The Tisch Cancer Institute Mount Sinai Hematology/Oncology Fellowship at the AACR ASCO #MCCR22 "Vail" workshop. What a phenomenal week learning to write robust clinical trials! 📝 📸: Vail faculty Karyn Goodman, MD, MS; Attendees Jr faculty Jon Feld, cofellows Rima Patel, Linda Wu, MD, Tarek Mouhieddine, MD
Wrapping up an incredible week of clinical trial development at AACR ASCO #MCCR. Grateful to be have met and worked with these amazing oncologists! Dionisia Quiroga, DO, PhD Roberto Leon-Ferre Shipra Gandhi Fauzia Riaz, MD, MHS @JingJiMD Julia McGuinness, MD, MS Tarek Mouhieddine, MD Sridevi Rajeeve, MD Linda Wu, MD
Excited to share our work on the correlation between Oncotype and Ki67 using the IKWG categories. Important to consider when using Ki67 in clinical practice, especially to guide adjuvant abemaciclib Joseph A. Sparano, MD Melanie Kier, MD, MBA Brittney Zimmerman The Tisch Cancer Institute
JUST IN: Gilead Sciences announced statistically significant OS from Phase 3 TROPiCS-02: SG antibody-drug conjugate prolongs OS in heavily-pretreated patients with HR+/HER2- metastatic breast cancer Dana-Farber’s Breast Oncology Center OncoAlert, via Business Wire businesswire.com/news/home/2022…
Updated results from #MONARCH3 at #ESMO22: addition of #abemaciclib to an aromatase inhibitor improves overall survival in endocrine sensitive advanced #bcsm (not significant at this interim analysis but to me clinically relevant: mOS=67 months, >1y gain) OncoAlert ESMO - Eur. Oncology
End-of-summer fellows & faculty picnic in Central Park replete with food, games, sun and camaraderie! 👏🏼 to our wellness committee - @AzziJacques Rima Patel Sridevi Rajeeve, MD Bailey Gleason Fitzgerald @orrinpail @RSJSheppard Wang Xuejun The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai
Our expert, Rima Patel will give poster presentations on her latest #BreastCancer research at #SABCS22. Be sure to visit her to learn more. Find out more about SABCS: mshs.co/3Bawct2 The Tisch Cancer Institute
Thank you OncLive.com for the opportunity to share our findings on the relationship between race, Ki67, and Oncotype as well as palliative care use in elderly patients with breast cancer.
Finally out in NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats Ann Partridge MD, MPH ETOP IBCSG Partners Foundation et al! OncoAlert #bcsm nejm.org/doi/full/10.10…
Huge congratulations to Icahn School of Medicine at Mount Sinai Mount Sinai Hematology/Oncology Fellowship graduating fellows #2023 👏🎓🌟 Good luck on starting stellar careers!!
